Travere Therapeutics Stock Return On Asset
| TVTX Stock | USD 18.81 0.11 0.59% |
Travere Therapeutics fundamentals help investors to digest information that contributes to Travere Therapeutics' financial success or failures. It also enables traders to predict the movement of Travere Stock. The fundamental analysis module provides a way to measure Travere Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Travere Therapeutics stock.
Return On Assets is likely to drop to -0.15 in 2024. Travere | Return On Asset |
Travere Therapeutics Company Return On Asset Analysis
Travere Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Travere Therapeutics Return On Asset | -0.26 |
Most of Travere Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Travere Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Travere Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Travere Therapeutics is extremely important. It helps to project a fair market value of Travere Stock properly, considering its historical fundamentals such as Return On Asset. Since Travere Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Travere Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Travere Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Travere Total Assets
Total Assets |
|
Based on the latest financial disclosure, Travere Therapeutics has a Return On Asset of -0.2614. This is 97.01% lower than that of the Biotechnology sector and 98.89% lower than that of the Health Care industry. The return on asset for all United States stocks is 86.71% higher than that of the company.
Travere Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Travere Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics of similar companies.Travere Therapeutics is currently under evaluation in return on asset category among its peers.
Travere Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Travere Therapeutics from analyzing Travere Therapeutics' financial statements. These drivers represent accounts that assess Travere Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Travere Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 601.2M | 1.3B | 1.9B | 1.3B | 667.7M | 572.6M | |
| Enterprise Value | 743.7M | 1.4B | 2.0B | 1.7B | 1.0B | 646.3M |
Travere Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Travere Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Travere Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Travere Fundamentals
| Return On Equity | -2.8 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.73) % | ||||
| Operating Margin | (0.89) % | ||||
| Current Valuation | 1.76 B | ||||
| Shares Outstanding | 87.03 M | ||||
| Shares Owned By Insiders | 0.65 % | ||||
| Shares Owned By Institutions | 98.96 % | ||||
| Number Of Shares Shorted | 6.97 M | ||||
| Price To Book | 76.10 X | ||||
| Price To Sales | 8.05 X | ||||
| Revenue | 145.24 M | ||||
| Gross Profit | (31.35 M) | ||||
| EBITDA | (326.25 M) | ||||
| Net Income | (376.33 M) | ||||
| Cash And Equivalents | 553.17 M | ||||
| Cash Per Share | 8.65 X | ||||
| Total Debt | 404.78 M | ||||
| Debt To Equity | 2.60 % | ||||
| Current Ratio | 4.71 X | ||||
| Book Value Per Share | (0.39) X | ||||
| Cash Flow From Operations | (280.02 M) | ||||
| Short Ratio | 5.10 X | ||||
| Earnings Per Share | (4.52) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 27.4 | ||||
| Number Of Employees | 380 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 1.64 B | ||||
| Total Asset | 788.91 M | ||||
| Retained Earnings | (1.13 B) | ||||
| Working Capital | 438.87 M | ||||
| Net Asset | 788.91 M |
About Travere Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Travere Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Travere Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Travere Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.